Drug Trial Radar · NCT06673927
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
104
Actual
Start
Dec 1, 2017
Primary completion
Nov 21, 2018
Study completion Mar 8, 2019
Sponsor
- Lead sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: 1. To evaluate the tolerability, safety of single and multiple doses of YZJ-1139 in healthy participants 2. To evaluate the pharmacokinetic of single and multiple doses of YZJ-1139 in healthy participants Secondary objectives: To explore the safe tolerated dose of YZJ-1139, provide data support for the design of phase II dosing regimen
Conditions
- Insomnia
Interventions
YZJ-1139Drug
Single oral dose, 2mg, 5mg, 10mg, 20mg, 40mg, 60mg, 80mg
YZJ-1139Drug
Multiple Dosing ,Each oral dose of 10 mg,20 mg,40 mg or 60 mg
PlaceboDrug
Placebo administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 to Day 3 post single dose;From Day 1 to Day 14 post multiple dose;
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Ditan Hospital Capital Medical University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.